Glioblastoma, also called glioblastoma multiforme, is a relatively common intracranial malignant tumor, and its survival period varies to a certain extent, which is mainly related to the individual’s physical condition, infiltration, metastasis or not, clinical stage and pathological type, and many other factors. In case of well-differentiated glioblastoma, the survival period can reach more than five years; in case of poorly-differentiated glioblastoma, the average survival period is usually about one and a half years or even shorter after treatment with targeted drugs, surgical resection or radiotherapy. The main clinical manifestations are a sharp increase in intracranial pressure and some nonspecific symptoms in neurology. The presence of an irregular, low-density, peripheral ring of enhancing lesions in the central area of the skull is evident by neuroimaging CT. Glioblastomas may show infiltrative growth in the brain, appearing colorful and accompanied by hemorrhage and necrosis. A few tumors may invade the cerebral cortex, resulting in widening of the cerebral gyrus and even involvement of the limbic and dural membranes. Therefore, the prognosis of most glioblastomas is relatively poor, and it is recommended that patients should consult the doctor in time to find out their existence and treat them early.